Loading
Life sciences · Journal article
Acs Macro Letters · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Platinum-based chemotherapy drugs are widely used in the treatment of various cancers due to their broad antitumor spectrum, but their clinical application is severely limited by significant systemic toxicity resulting from nonspecific cytotoxicity. Prostate-specific membrane antigen (PSMA), which is highly overexpressed in most prostate cancer (PCa) cells, presents a promising target for tumor-selective drug delivery. In this study, we designed and synthesized a novel dual-targeting nanoplatform that combines metabolic glycan labeling and bioorthogonal chemistry for the precise delivery of oxaliplatin (OXP) to PSMA-positive prostate cancer cells. The nanoplatform (DDM-NPs) is functionalized with DUPA, a high-affinity PSMA ligand, and encapsulates Ac4ManNAz for metabolic cell surface engineering. Subsequently, a bioorthogonal reaction between the azido-labeled cells and the bicyclo[6.1.0]non-4-yne (BCN)-conjugated prodrug (BCN-OXP) enhanced cellular uptake and cytotoxicity in PSMA-high-expressed cell lines (22Rv1) compared to PSMA-low-expressed cells (PC-3) in vitro and in vivo. Our work establishes a promising strategy to enhance the therapeutic index of platinum drugs through active targeting and bioorthogonal reactions, offering a potential avenue for more effective and safer prostate cancer therapy.